Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press483BONE SARCOMASСАРКОМЫ КОСТЕЙLocal antibacterial prophylaxis in oncoorthopedicsЛокальная антибиотикопрофилактика раневой инфекции в онкоортопедииTeplyakovV. V.ТепляковВ. В.
Russian Federation

Moscow

oncolog59@yandex.ruBukcharovA. V.БухаровА. В.
Russian Federation

Moscow

DerzhavinV. A.ДержавинВ. А.
Russian Federation

Moscow

P.A. Gertzen Moscow Cancer Research CenterФГБУ Московский научно-исследовательский онкологический институт им. П.А. Герцена МЗ РФ270120146149522701202227012022Copyright ©; 2014, Teplyakov V.V., Bukcharov A.V., Derzhavin V.A.Copyright ©; 2014, Тепляков В.В., Бухаров А.В., Державин В.А.2014Teplyakov V.V., Bukcharov A.V., Derzhavin V.A.Тепляков В.В., Бухаров А.В., Державин В.А.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/483

Forty surgical resections with intraoperative use of collagen sponges (Collatamp® EG) impregnated with antibiotic (gentamicin) were performed. The average age of patients was 45 (from 18 to 65). There were no infection complications in the early postoperative period. Collatamp EG can be recommended for orthopaedical patients with high risk of wound infection as additional agent for local antibiotic prophylaxis.

Выполнено 40 хирургических вмешательств с интраоперационным использованием коллагеновых губок (Collatamp® EG) с антибиотиком (гентамицин). Средний возраст пациентов составил – 45 лет (от 18 до 65 лет). Ранних послеоперационных инфекционных осложнений не наблюдалось. Препарат Collatamp EG можно рекомендовать к применению у онкоортопедических пациентов с высоким риском развития раневой инфекции в качестве дополнительного средства локальной антибиотикопрофилактики.

perioperative antibiotic prophylaxiswound infectionsинтраоперационная антибиотикопрофилактикаинфекционные осложнения1. Parvizi J., Azzam K., Ghanem E., Austin M.S., Rothman R.H. Periprosthetic Infection Due to Resistant Staphylococci. Clin. Orthop. Relat. Res. 2009, p. 467.Parvizi J., Azzam K., Ghanem E., Austin M.S., Rothman R.H. Periprosthetic Infection Due to Resistant Staphylococci. Clin. Orthop. Relat. Res. 2009, p. 467.2. Phillips J.E., Crane T.P., Noy M., Elliott T.S., Grimer R.J. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J. Bone Joint Surg. Br 2006, v. 88, p. 943-948.Phillips J.E., Crane T.P., Noy M., Elliott T.S., Grimer R.J. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J. Bone Joint Surg. Br 2006, v. 88, p. 943-948.3. Cavanaugh D., Berry J., Yarboro S. et al. Better Prophylaxis Against Surgical Site Infection with Local as Well as Systemic Antibiotics. J. of Bone and Joint Surgery Am. 2009, p. 1907-1911.Cavanaugh D., Berry J., Yarboro S. et al. Better Prophylaxis Against Surgical Site Infection with Local as Well as Systemic Antibiotics. J. of Bone and Joint Surgery Am. 2009, p. 1907-1911.4. Trampuz A., Widmer A.F. Infections associated with orthopaedic implants. Curr. Opin. Infect. Dis. 2006, v. 19, p. 349-356.Trampuz A., Widmer A.F. Infections associated with orthopaedic implants. Curr. Opin. Infect. Dis. 2006, v. 19, p. 349-356.5. Engesaeter L.B., Lie S.A., Espehaug B. et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop. Scand. 2003, v. 74 (6), p. 644-651.Engesaeter L.B., Lie S.A., Espehaug B. et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop. Scand. 2003, v. 74 (6), p. 644-651.6. Pulido L., Ghanem E., Joshi A., Purtill J.J., Parvizi J. Periprosthetic Joint Infection. Clin. Orthop. Relat. Res. 2008, v. 466, p. 1710-1715.Pulido L., Ghanem E., Joshi A., Purtill J.J., Parvizi J. Periprosthetic Joint Infection. Clin. Orthop. Relat. Res. 2008, v. 466, p. 1710-1715.7. Neut D., van de Belt H., van Horn J.R. et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials. 2003, v. 24 (10), p. 1829-1831.Neut D., van de Belt H., van Horn J.R. et al. Residual gentamicin-release from antibiotic-loaded polymethylmathacrylate beads after 5 years of implantation. Biomaterials. 2003, v. 24 (10), p. 1829-1831.8. Mendel V., Simanowski H., Scholz H. et al. Therapy with gentamicin-PMMA beads, gentamicin-collagen sponge, and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats. Arch. Orthop. Trauma Surg. 2005, v. 125 (6), p. 363-368.Mendel V., Simanowski H., Scholz H. et al. Therapy with gentamicin-PMMA beads, gentamicin-collagen sponge, and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats. Arch. Orthop. Trauma Surg. 2005, v. 125 (6), p. 363-368.